QMA

Anbio Biotechnology Class A Ordinary Shares (NNNN) — QMA analysis

Sector: Healthcare · Market cap: $973M · Price: $3,71 · Data as of 2026-10-22

44
/100
D
Composite grade
Higher score than 53% of 22,733 tracked stocks

Anbio Biotechnology Class A Ordinary Shares has a below-average composite score of 44/100, higher score than 53% of 22,733 tracked stocks. The highest-scoring layer is Earnings quality; the lowest is Insider activity.

Analytical score, not investment advice. No score is an instruction or a guarantee. Past performance ≠ future results.

What 9 data layers say about NNNN

The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.

LayerScore
Fundamental value (FVS)43/100
Earnings quality (EQS)70/100
Technical trend (TSS)37/100
Relative strength (RS)12/100
Momentum (USS)52/100
Insider activity (IAS)0/100
Off-exchange trading (FINRA) / large flows (WHS)40/100
Institutional 13F (IFS)70/100
Catalysts (XS)35/100

What does the QMA model currently show for Anbio Biotechnology Class A Ordinary Shares?

The composite score is a research starting point, not an instruction. What matters is layer confluence — whether the layers point in the same direction.

For NNNN the layers diverge — some score high (Earnings quality), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.

NNNN insider & smart money activity

For NNNN we track the institutional footprint through FINRA off-exchange trading data (WHS 40/100) and reported 13F positions, filed with up to a 45-day delay (IFS 70/100). Detailed insider data for this stock is still being collected.

How NNNN compares

Similar stocks from the same sector:

Frequently asked questions

What is the composite score for NNNN stock?

44/100 (D) — Data as of 2026-10-22.

Are insiders buying NNNN stock?

—

Where can I see live NNNN data?

Live NNNN data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.

Free registration, no card — trial full access, then the free plan

Open NNNN detail →

Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.

⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.

Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]